Secondary amenorrhea in a woman with spinocerebellar degeneration treated with thyrotropin-releasing hormone: a case report and in vitro analysis by Kanasaki, Haruhiko et al.
CASE REPORT Open Access
Secondary amenorrhea in a woman with
spinocerebellar degeneration treated with
thyrotropin-releasing hormone: a case report and
in vitro analysis
Haruhiko Kanasaki
*, Aki Oride, Tselmeg Mijiddorj, Indri Purwana and Kohji Miyazaki
Abstract
Introduction: While thyrotropin-releasing hormone is known to be a prolactin-release stimulating factor,
thyrotropin-releasing hormone-tartrate and its derivative, taltirelin hydrate, are used for the treatment of
spinocerebellar degeneration, a degenerative disease characterized mainly by motor ataxia. We report the case of a
patient being treated with a thyrotropin-releasing hormone preparation for spinocerebellar degeneration who
developed amenorrhea after a dose increase. Her hormonal background was analyzed and the effect of prolonged
exposure to thyrotropin-releasing hormone on pituitary prolactin-producing cells was examined in vitro.
Case presentation: Our patient was a 36-year-old Japanese woman who experienced worsening of gait
disturbance at around 23 years of age, and was subsequently diagnosed as having spinocerebellar degeneration.
She had been treated with thyrotropin-releasing hormone-tartrate for four years. Taltirelin hydrate was added to
the treatment seven months prior to her presentation, followed by an improvement in gait disturbance. Around
the same period, she started lactating and subsequently developed amenorrhea three months later. Taltirelin
hydrate was discontinued and she was referred to our hospital. She was found to have normal sex hormone levels.
A thyrotropin-releasing hormone provocation test showed a normal response of thyroid-stimulating hormone level
and an over-response of prolactin at 30 minutes (142.7 ng/mL). Resumption of menstruation was noted three
months after dose reduction of thyrotropin-releasing hormone. In our in vitro study, following long-term exposure
to thyrotropin-releasing hormone, cells from the rat pituitary prolactin-producing cell line GH3 exhibited an
increased basal prolactin promoter activity but showed a marked decrease in responsiveness to thyrotropin-
releasing hormone.
Conclusions: Physicians should be aware of hyperprolactinemia-associated side effects in patients receiving
thyrotropin-releasing hormone treatment. Long-term treatment with a thyrotropin-releasing hormone preparation
might cause a large amount of prolactin to accumulate in prolactin-producing cells and be released in response to
exogenous thyrotropin-releasing hormone stimulation.
Introduction
Thyrotropin-releasing hormone (TRH) is a hypothalamic
hormone discovered as a peptide that promotes the release
of thyroid-stimulating hormone (TSH) from the anterior
pituitary gland [1]. TRH is also known to be a prolactin
(PRL)-releasing factor [2] and the TRH provocation test is
widely performed to evaluate the ability to secrete PRL.
TRH-tartrate (TRH-T) is used as a diagnostic agent for
hyperprolactinemia in gynecological practice. TRH-T has
also been shown to be effective in improving gait distur-
bance and trunk sway caused by spinocerebellar degenera-
tion (SCD), an intractable neurological disorder, and has
been widely used in clinical practice [3]. Taltirelin hydrate
was subsequently developed as an orally administered
TRH derivative and has been used as a safe central ner-
vous system (CNS)-selective agent for the treatment of
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ered to activate the signal transduction system of the CNS.
At the same time, both agents mimic TRH and thus may
affect endocrine function in women. We describe here the
case of a patient with SCD who developed secondary ame-
norrhea suspected to have been induced by the use of
TRH-T and its derivative taltirelin hydrate.
Case presentation
Our patient was a 36-year-old Japanese woman who had
been pregnant three times and had given birth to three
children. She had experienced mild gait disturbance since
she was around two years of age but the cause had
remained uncertain. She noted worsening of the gait dis-
turbance around age 23 and was subsequently diagnosed
as having SCD at age 31 when she gave birth to her sec-
ond child through vaginal delivery. Treatment was
started with 2 mg of TRH-T (Hirtonin, Takeda Pharma-
ceutical Co., Osaka, Japan) given intravenously once or
twice a month. Taltirelin hydrate (10 mg/day) (Ceredist,
Tanabe-Mitsubishi Pharma Corp., Osaka, Japan) was
added to the treatment one year prior to presentation,
followed by a significant improvement in gait distur-
bance. Around the same time, she started lactating and
experiencing irregular menstruation. Three months after
the addition of taltirelin hydrate, she developed amenor-
rhea and presented at this time to our obstetrics and
gynecological department. Her hematological test results
at presentation are summarized in Table 1. On examina-
tion, no abnormal findings were observed in either sex
hormone levels (luteinizing hormone (LH) 9.6 mIU/mL,
follicle-stimulating hormone (FSH) 5.7 mIU/mL, estra-
diol (E2) 69 pg/mL and PRL 11.2 ng/mL) or thyroid func-
tion (fT3 2.2 pg/mL, fT4 0.9 nf/dL, TSH 1.26 μU/mL).
Complete blood count and biochemical tests were also
normal. Pelvic examination and endovaginal ultrasono-
graphy revealed no abnormalities in the uterus or ovaries,
such as polycystic ovary.
Administration of E2 and progesterone induced with-
drawal bleeding. The hormone provocation test was per-
formed five days after the start of this bleeding and the
results are summarized in Figure 1. Her LH level was
7.5 mIU/mL at baseline and increased to 39.7, 35.9,
31.7, and 30.9 mIU/mL at 30, 60, 120, and 180 minutes,
respectively, after provocation with 100 μg LH-releasing
hormone (RH) (Figure 1A). Her basal FSH level was
3.1 mIU/mL and the levels at the corresponding time
points after LH-RH provocation were 4.4, 5.2, 4.9, and
5.0 mIU/mL (Figure 1B). Her basal LH level was higher
than her basal FSH level, and her LH level, but not her
FSH level, showed a mild over-response to the provoca-
tion with LH-RH. In the provocation test with 500 μg
TRH, her TSH level showed a normal response with
levels of 1.55 μU/mL at baseline and 23.4, 17.69, 12.93,
and 10.15 μU/mL at 30, 60, 90, and 120 minutes,
respectively, after provocation (Figure 1C), whereas her
PRL level exhibited an over-response with levels of 7.1
ng/mL at baseline and 142.7, 84.6, 56.8, and 48.2 ng/mL
at 30, 60, 90, and 120 minutes, respectively, after provo-
cation (Figure 1D). The results led to a diagnosis of
latent hyperprolactinemia. An MRI scan of the head was
performed but revealed no abnormal findings in her
pituitary gland. Given that withdrawal bleeding was
induced by the administration of an E2/progesterone
preparation, it was explained to our patient that regular
induction of withdrawal bleeding was considered neces-
sary. Taltirelin hydrate (Ceredist) was discontinued at
the discretion of a physician, followed by the return of
menstruation three months later. This also resulted in
cessation of lactation.
Our patient showed a normal basal PRL level following
long-term administration of the TRH agonist, but exhib-
ited over-response of PRL in the provocation test. We
subsequently investigated the effect of long-term admin-
istration of TRH on PRL-producing cells using GH3
cells, a rat-derived PRL-producing cell line. GH3 cells
were pre-cultured in the presence or absence of 100 nM
TRH for 48 hours. After the culture medium was
exchanged (TRH was removed), the cells were continu-
ously stimulated with 100 nM TRH for six hours and
measured for PRL promoter activity. The cells that were
not exposed to the 48-hour pre-treatment with TRH
Table 1 Laboratory findings
Parameter Value
White blood cell count 3220 cells/μL
Red blood cell count 4.04 × 106 cells/μL
Hemoglobin 11.9 g/dL
Hematocrit 36.7%
Platelets 171 × 10
3 cells/μL
Total protein 6.6 g/dL
Albumin 4.3 g/dL
Total bilirubin 0.7 mg/dL
Aspartate aminotransferase 15 IU/L
Alanine aminotransferase 13 IU/L
Blood urea nitrogen 11.2 mg/dL
Creatine 0.58 mg/dL
Na 143 mEq/L
K 3.9 mEq/mL
Cl 105 mEq/mL
Free T3 2.2 pg/mL
Free T4 0.9 ng/dL
Thyroid-stimulating hormone 1.26 μU/mL
Leutenizing hormone 9.6 mIU/mL
Follicle-stimulating hormone 5.7 mIU/mL
Estradiol 69 mIU/mL
Prolactin 11.2 ng/mL
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activity in response to TRH stimulation, compared with
controls. For the cells pre-treated with TRH for 48 hours
(TRH-treated cells), basal promoter activity increased by
2.41 ± 0.25-fold and the activity increased by 3.31 ± 0.42-
fold following stimulation with TRH (rates of increase
were relative to the TRH-untreated control set as 1.0).
The PRL promoter activity of the TRH-treated cells
increased by 1.37-fold following TRH stimulation (3.31/
2.41 = 1.37) (Figure 2).
Discussion
Gynecologists generally recognize TRH as the agent used
in the TRH provocation test, but are not necessarily aware
that this agent is also routinely used for the treatment of
SCD, a neurological disorder. Our patient had been diag-
nosed as having SCD and treated with TRH-tartrate for a
long period until she subsequently started receiving
another TRH agonist, taltirelin hydrate, and developed
amenorrhea. Although the basal secretion level of PRL was
within the normal range, an over-response in PRL secre-
tion was noted in the TRH provocation test, suggesting
latent hyperprolactinemia. TRH, a hypothalamic hormone,
was originally discovered as a central factor that stimulates
the anterior pituitary gland to secrete TRH and thereby
regulates thyroid hormone secretion [1]. The hormone was
later found to promote PRL secretion when applied to rat
pituitary cells [6] or when intravenously infused to humans
[7]. Since then, the hormone has also been recognized as a
substance for promoting the secretion of PRL. Therefore,
at the initial presentation of our patient to our hospital, we
speculated that the excessive dosing of TRH might have
induced hyperprolactinemia and subsequent amenorrhea.
However, a sex hormone test at that time showed no evi-
dence of hyperprolactinemia, with a PRL level of 11.2 ng/
mL, which was within the normal range. Although a high
basal LH level was noted (LH 9.6 mIU/mL, FSH 5.7 mIU/
mL), transvaginal ultrasonography did not show polycystic
ovary, which did not meet the new criteria for diagnosing
polycystic ovarian syndrome as proposed by the Reproduc-
tion and Endocrine Committee of the Japan Society of
Obstetrics and Gynecology (2007). Given that a hormone
provocation test showed a marked increase in the PRL
level from 7.1 ng/mL before provocation to 142.7 ng/mL
Figure 1 Luteinizing hormone releasing hormone (LH-RH) and thyrotropin-releasing hormone (TRH) provocation test results from our
patient.L H(A) and follicle-stimulating hormone (FSH) (B) release by LH-RH provocation test. Thyroid-stimulating hormone (TSH) (C) and
prolactin (PRL) (D) release by TRH provocation test.
Kanasaki et al. Journal of Medical Case Reports 2011, 5:567
http://www.jmedicalcasereports.com/content/5/1/567
Page 3 of 630 minutes after provocation with TRH, our patient was
considered to have latent hyperprolactinemia with abnor-
mal lactation and menstruation. What are considered nor-
mal values for serum PRL differs according to the assay
system used. The chemiluminescence immunoassay
(CLIA) we currently use defines normal serum PRL levels
as 3.2 to 26.2 ng/mL. Although there are no standard cri-
teria for the diagnosis of latent hyperprolactinemia using
recent assay systems, we diagnosed latent hyperprolactine-
mia based on the observation that serum PRL increased to
more than 140 ng/mL after the TRH provocation test,
serum PRL was increased more than 20-fold by TRH, and
that our patient had symptoms associated with
hyperprolactinemia.
We then examined whether this in vivo condition can
be reproduced in vitro using prolactin-producing cells.
GH3 cells are somatolactotrophs derived from rat pitui-
tary tumor and produce/secrete PRL and growth hor-
mone (GH). These cells are widely used as model cells
for the elucidation of the regulation mechanism of PRL
production, as they share many characteristics with nor-
mal lactotrophs and somatolactotrophs in addition to
secreting PRL and GH in response to stimulation with
TRH [8,9]. To examine the effect of long-term stimula-
tion with TRH on GH3 cells, we cultured GH3 cells in
the presence of TRH for 48 hours and evaluated their
responsiveness to TRH stimulation by measuring PRL
promoter activity. The GH3 cells continuously stimulated
Figure 2 Response to thyrotropin-releasing hormone (TRH) on prolactin promoter activity in TRH-treated cells. GH3 cells were treated
or non-treated with 100 nM TRH for 48 hours in 1% fetal bovine serum (FBS)-containing Dulbecco’s modified Eagle medium (DMEM). Then, the
culture medium was washed with and changed to serum-free DMEM. Next, the cells were stimulated with 100 nM TRH for six hours. Luciferase
activity was measured and relative induction is shown (relative to TRH-untreated control set as 1.0). **P < 0.01 versus controls in TRH non-
treated cells. The difference between TRH stimulation in non-treated cells and treated cells was not statistically significant.
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basal PRL promoter activity compared with TRH-
untreated control cells. This indicated that the PRL pro-
moter was activated by persistent stimulation with TRH,
leading to the activation of intracellular PRL synthesis.
Intracellularly produced PRL proteins are released as
secretary granules in response to TRH while maintaining
a certain level of basal secretion. Given the results of the
in vitro experiment, it was expected that long-term treat-
ment with TRH would cause hyperprolactinemia. How-
ever, our patient showed no increase in the basal PRL
level even after continuous treatment with TRH. The
cells pre-treated with TRH for 48 hours only exhibited a
1.37-fold increase in PRL secretion compared with the
controls in response to subsequent TRH stimulation. In
vivo (that is, in our patient), the basal PRL level was 7.1
ng/mL, which was within the normal range, but increased
by about 20-fold to 142.7 ng/mL 30 minutes after TRH
stimulation. Thus, different responses to stimulation fol-
lowing continuous administration of TRH were observed
in vitro and in vivo.
Although it is not possible to make a direct comparison
of the in vitro and in vivo responses (because PRL secre-
tion was measured in vivo while PRL promoter activity
was measured in vitro), there was at least a difference in
the response to TRH after long-term exposure to it.
In vivo, the secretion and synthesis of PRL have been
s h o w nt ob ed o w n - r e g u l a t e dm a i n l yb yd o p a m i n eD 2
receptor agonists [10] and this mechanism is utilized in
the treatment of pituitary tumor and other therapeutic
applications. PRL has also been known to be up-regulated
by various hypothalamic hormones other than TRH or
anterior pituitary hormones [11]. The in vitro experiment
in this study only evaluated the effect of long-term TRH
treatment on homogeneous PRL-producing cells and did
not consider its effects on other hypothalamic hormones,
such as dopamine, or cells secreting hormones other than
PRL. Moreover, our patient had been treated with TRH-T
(Hirtonin) alone for four years before combination therapy
with Hirtonin and taltirelin hydrate (Ceredist) was started.
In the in vitro experiment, however, a 48-hour treatment
of cells with TRH was used to model the long-term
administration of TRH in our patient. This might have
contributed to the differences observed in vitro and in
vivo. At the same time, in vivo PRL transcription activity
was increased by approximately 2.5-fold following the 48-
hour treatment with TRH. TRH stimulation activates var-
ious signal transmitters. In particular, the activation of
extracellular signal-regulated kinase (ERK) mediated by
protein kinase C (PKC) plays an important role in the
expression of the PRL gene. Therefore, PRL gene expres-
sion is suppressed by inhibitors of these kinases. However,
studies examining TRH-mediated PRL secretion have
shown that PRL secretion is not suppressed by PKC/ERK
inhibitors, but is instead strongly suppressed by calcium-
dependent kinase inhibitors [8]. Our patient showed no
increase in basal PRL level but showed an over-response
to TRH. This can possibly be attributed to the long-term
treatment with a TRH preparation that might have caused
the accumulation of a large amount of PRL in PRL-produ-
cing cells and subsequent massive release of the hormone
in response to exogenous TRH stimulation.
Conclusions
We report the case of a patient who was treated with a
TRH preparation for SCD who developed amenorrhea fol-
lowing a dose increase. Our patient had a normal PRL
l e v e lb u ts h o w e dar e s p o n s ep a t t e r ns u g g e s t i v eo fl a t e n t
hyperprolactinemia following stimulation with TRH. Phy-
sicians should be cognizant of hyperprolactinemia-asso-
ciated side effects in patients receiving TRH treatment.
The experiment using PRL-producing cells demonstrated
that long-term exposure to TRH resulted in increased
basal activity of PRL synthesis and decreased responsive-
ness to TRH. Thus, different responses to TRH were
observed in vivo and in vitro following the long-term
administration of TRH.
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